Chronic Obstructive Pulmonary Disease Clinical Trial
Official title:
A Study About Association Between Microbiome, Metabolome and Clinical Characteristics in COPD Patients
Verified date | October 2023 |
Source | Asan Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
The goal of this observational registry study is to compare characteristics of gut and sputum microbiome and metabolome among COPD patients with significant smoking history, COPD patients without significant smoking history and healthy smoker. Additionally, the investigators investigate the difference of blood metabolites and peripheral blood mononuclear cells level among groups. The main questions it aims to answer are: - Are there significant difference in fecal or sputum microbiome and metabolome between COPD patients and healthy smoker? - Are there any distinct characteristics in microbiome and metabolome in COPD with COPD patients with significant smoking history, COPD patients without significant smoking history compared with healthy smoker? - Are there any difference in blood metabolites and peripheral blood mononuclear cells levels among patients with significant smoking history, COPD patients without significant smoking history and healthy smoker - Might distinct characteristics of microbiome and metabolites in COPD patients be related to worse clinical outcomes in COPD patients?
Status | Not yet recruiting |
Enrollment | 300 |
Est. completion date | December 31, 2028 |
Est. primary completion date | June 30, 2028 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - COPD Patients, defined by FEV1/FVC <0.7, who - agree with informed consent - have no history of acute exacerbation within 3 months - Healthy smoker without airflow limitation, defined by FEV1/FVC =0.7, who - have smoking history with at least 30 pack-year - agree with informed consent - do not use medication for chronic respiratory disease Exclusion Criteria: - Withdrawal of informed consent - History of acute exacerbation or antibiotics use within 3 months - Difficulty to collect adequate stool, sputum and blood samples |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Asan Medical Center | HEM Pharma Inc., Seoul National University College of Medicine |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Shannon diversity index | the investigators will compare alpha diversity and community similarity among groups by using the Shannon diversity index. | At enrollment | |
Primary | Simpson index | the investigators will compare alpha diversity and community similarity among groups by using the Simpson index. | At enrollment | |
Primary | Principal component analysis | the investigators will compare beta diversity and community similarity among groups by using the principal component analysis. | At enrollment | |
Primary | Microbiome composition by metagenomic analysis | The composition of microbiome will be presented as bar graph. | At enrollment | |
Primary | Peripheral blood mononuclear cells level | the investigators will compare the Peripheral blood mononuclear cells level among groups | At enrollment | |
Primary | Acetic acid level | the investigators will compare the acetic acid level among groups | At enrollment | |
Primary | Propionic acid level | the investigators will compare the Propionic acid level among groups | At enrollment | |
Primary | Isobutyric acid level | the investigators will compare the Isobutyric acid level among groups | At enrollment | |
Primary | Butyric acid level | the investigators will compare the butyric acid level among groups | At enrollment | |
Primary | Isovaleric acid level | the investigators will compare the Isovaleric acid level among groups | At enrollment | |
Primary | Valeric acid level | the investigators will compare the valeric acid level among groups | At enrollment | |
Primary | dimethylglycine level | the investigators will compare the dimethylglycine level among groups | At enrollment | |
Primary | secondary bile acid level | the investigators will compare the secondary bile acid level among groups | At enrollment | |
Secondary | Difference of microbiome according to Exacerbation | the investigators will investigate the baseline difference of microbiome between COPD patients with moderate to severe exacerbation and COPD patients without moderate to severe exacerbation | within 1 year after enrollment | |
Secondary | Difference of metabolome according to Exacerbation | the investigators will investigate the baseline difference of metabolome between COPD patients with moderate to severe exacerbation and COPD patients without moderate to severe exacerbation | within 1 year after enrollment | |
Secondary | Difference of microbiome according to death | the investigators will investigate the baseline difference of microbiome between COPD patients with death and COPD patients without death | within 1 year after enrollment | |
Secondary | Difference of metabolome according to death | the investigators will investigate the baseline difference of metabolome between COPD patients with death and COPD patients without death | within 1 year after enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|